Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Cabozantinib Plus Atezolizumab Extends PFS for Frontline HCC in COSMIC-312 Trial
New data for management of hepatocellular carcinoma
![COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram](https://www.researchgate.net/publication/351523048/figure/fig4/AS:1028856655908867@1622309950788/COSMIC-312-Study-Design-Reproduced-with-permission-from-Kelley-et-al-91.png "COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram")
COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology
Phase III Trial of Cabozantinib and Atezolizumab vs Sorafenib in Advanced Hepatocellular Carcinoma - The ASCO Post
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review - ScienceDirect
晚期肝癌：卡博替尼+阿替利珠单抗的3 期研究结果- whyes 的博客
File:"Cosmic Cliffs" in the Carina Nebula (NIRCam Compass Image) (2022-031).png - Wikimedia Commons
![COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram](https://www.researchgate.net/publication/351523048/figure/fig1/AS:1028856655925253@1622309950697/Antitumor-and-immunomodulatory-activity-of-cabozantinib-14-16-17-28-31-35-38-40-41-The_Q320.jpg "COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram")
COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram
Josh Allen 2022 Select Suite Level Cosmic #312 Price Guide - Sports Card Investor
Dr Joseph McCollom DO on X: "Combos, combos combos! Dr Lipika Goyal from @MGHCancerCenter discusses combining TKIs and #IO with COSMIC-312, LEAP-002 and early phase Lenva + Pembro 1st line for #HCC #
Phase 3 COSMIC-312 Study in Advanced HCC
Dr Joseph McCollom DO on X: "Combos, combos combos! Dr Lipika Goyal from @MGHCancerCenter discusses combining TKIs and #IO with COSMIC-312, LEAP-002 and early phase Lenva + Pembro 1st line for #HCC #
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoi
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer | Business Wire
Lancet Oncol：COSMIC-312——肝癌免疫治疗之谜--生命经纬
晚期肝癌：卡博替尼+阿替利珠单抗的3 期研究结果- whyes 的博客
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology
Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma - Gray - 2023 - Liver Cancer International - Wiley Online Library
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
![COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram](https://www.researchgate.net/publication/351523048/figure/fig4/AS:1028856655908867@1622309950788/COSMIC-312-Study-Design-Reproduced-with-permission-from-Kelley-et-al-91_Q320.jpg "COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram")
COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram
Book: Cosmic Collisions – The Hubble Atlas of Merging Galaxies | ESO Sverige
HCC CONNECT on X: "#ESMOasiaweek21: this is the place to be for clinical practice changing in advanced #hepatocellularcarcinoma! After ESMO Asia 2019 with #IMbrave150, we are waiting for the presentation of COSMIC-312
Current Oncology | Free Full-Text | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
